Puma Biotechnology(PBYI)
LOS ANGELES, CABiotechnology
Focus: Puma Biotechnology is a Los Angeles-based oncology-focused biotech company founded in 2010, publicly traded on NASDAQ (PBYI). The company specializes in the acquisition and development of cancer therapies with a peak-stage commercial asset.
Profile data last refreshed Yesterday · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
10
Should You Work at Puma Biotechnology?
AI assessmentBest suited for oncology professionals seeking stability in a profitable, focused biotech with meaningful commercial operations, but career progression depends entirely on neratinib's continued commercial success and Phase 3 pipeline readouts.
Why Work Here
- Established commercial infrastructure with $236M FY2025 revenue from FDA-approved oncology drug with expanding indications across breast cancer, lung cancer, and solid tumors
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$236M
Key Products
$37M Part D spendingGrowing
Peak
Help build intelligence for Puma Biotechnology
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.